Literature DB >> 29968153

mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells.

Yuting Deng1,2, Jiao Yang1,2, Feifei Luo1,2,3, Jing Qian1, Ronghua Liu1, Dan Zhang1,2, Hongxiu Yu4, Yiwei Chu5,6.   

Abstract

Immune cell activation occurs concurrently with metabolic reprogramming. As important components of the tumor microenvironment, monocytic myeloid-derived suppressor cells (M-MDSCs) are featured by their potent immunosuppressive abilities on anti-tumor effector cells. However, little is known about the contribution of metabolic adaptations to their suppressive roles. In this study, we found that tumor-infiltrating M-MDSCs had the same phenotype with splenic M-MDSCs. Compared with splenic M-MDSCs, tumor-infiltrating M-MDSCs exhibited stronger suppressive activities which was accompanied by higher glycolysis. Inhibition of glycolysis impaired the suppressive function of tumor M-MDSCs. Meanwhile, the results demonstrated that mTOR was responsible for this function regulation. mTOR inhibition by rapamycin decreased the glycolysis and reduced the suppressive activities of these cells. Furthermore, rapamycin treatment inhibited the tumor growth and reduced the percentage of M-MDSCs in 3LL tumor bearing mice. These results demonstrated that modulation of metabolism in immune cells can be an effective way to enhance anti-tumor effects.

Entities:  

Keywords:  Glycolysis; Immunotherapy; MDSC; mTOR

Mesh:

Substances:

Year:  2018        PMID: 29968153     DOI: 10.1007/s00262-018-2177-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  20 in total

Review 1.  Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy.

Authors:  Qing Li; Ming Xiang
Journal:  Acta Pharmacol Sin       Date:  2021-09-24       Impact factor: 7.169

2.  PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT.

Authors:  Yan Cui; Xuena Li; Bulin Du; Yao Diao; Yaming Li
Journal:  Cancer Manag Res       Date:  2020-07-27       Impact factor: 3.989

Review 3.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432

Review 4.  Engineering CAR-T Cells for Improved Function Against Solid Tumors.

Authors:  Michael A Morgan; Axel Schambach
Journal:  Front Immunol       Date:  2018-10-29       Impact factor: 7.561

Review 5.  AMPK activation inhibits the functions of myeloid-derived suppressor cells (MDSC): impact on cancer and aging.

Authors:  Antero Salminen; Anu Kauppinen; Kai Kaarniranta
Journal:  J Mol Med (Berl)       Date:  2019-05-25       Impact factor: 4.599

Review 6.  Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer.

Authors:  Yufei Wang; Anna Jia; Yujing Bi; Yuexin Wang; Guangwei Liu
Journal:  Cells       Date:  2020-04-18       Impact factor: 6.600

Review 7.  Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells.

Authors:  Jihyun Lim; Aram Lee; Hee Gu Lee; Jong-Seok Lim
Journal:  Biomol Ther (Seoul)       Date:  2020-01-01       Impact factor: 4.634

Review 8.  Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance.

Authors:  Łukasz Zadka; Damian J Grybowski; Piotr Dzięgiel
Journal:  Cell Oncol (Dordr)       Date:  2020-06-02       Impact factor: 6.730

Review 9.  Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.

Authors:  Yuhui Yang; Chunyan Li; Tao Liu; Xiaofang Dai; Alexandr V Bazhin
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

10.  The effects of age and systemic metabolism on anti-tumor T cell responses.

Authors:  Jefte M Drijvers; Arlene H Sharpe; Marcia C Haigis
Journal:  Elife       Date:  2020-11-10       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.